Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01548144 · ClinicalTrials.gov registry record · Phase 1
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 178
- Enrollment target
NCT01548144: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01548144 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 178 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01548144, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 178 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed) or of the combination of 3 study drugs that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied. Crizotinib is designed to block a protein called ALK, which is involved in cancer cell growth and survival. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Pemetrexed is designed to block proteins that may cause tumors to grow. This is an investigational study. Crizotinib is FDA approved and commercially available for the treatment of locally advanced or metastatic non-small cell lung cancer. Pazopanib is FDA approved and commercially available for treatment of advanced renal cell carcinoma. Pemetrexed is FDA approved and commercially available for the treatment of non-small cell lung cancer. The combination of crizotinib with pazopanib, crizotinib with pemetrexed, pazopanib with pemetrexed, and giving all 3 drugs together to patients with advanced cancer is investigational. Up to 364 patients will take part in this study. All will be enrolled at MD Anderson.
Interventions
- DRUG Pemetrexed
- DRUG Pazopanib
- DRUG Crizotinib (Xalkori)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2012-04 |
| Est. Completion | 2021-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01548144
The ClinicalTrials.gov registry entry for NCT01548144 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pemetrexed is the first listed.
NCT01548144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01548144 about?
NCT01548144 is a clinical study titled "Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer". The goal of this clinical research study is to find the highest tolerable dose of the combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed) or of the combination of 3 study drugs that can be given to patients with advanced cancer. The safety of these drug combin...
What is the current status of trial NCT01548144?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2012-04. Estimated completion is 2021-08-26.
What interventions are being tested in trial NCT01548144?
The interventions under investigation include: Pemetrexed (DRUG), Pazopanib (DRUG), Crizotinib (Xalkori) (DRUG).
Who is sponsoring clinical trial NCT01548144?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.